India-based CDMOs have detected an uptick in biopharma client interest in their biologics and early-phase clinical offerings – and these manufacturers are accordingly adjusting their growth…
News Category: Media
Indian CDMOs expand capacities: Syngene and Aragen lead the way
Making good on its promise, contract development and manufacturing organization (CDMO) Syngene has confirmed its Bengaluru biologics facility will be operational in the second half…
Contract Manufacturing: Pharma’s New Growth Pill
AURIGENE PHARMACEUTICAL services, a subsidiary of Dr Reddy’s Laboratories, has lined up big expansion in biologics over next three years. As a start, it is…
Aragen’s Formulation Manufacturing Facility Achieves GMP Certification from Telangana Drugs Control Administration
Certification Marks a Milestone for Aragen, Reinforcing Commitment to Quality and Regulatory Compliance in Pharmaceutical Manufacturing. Aragen is pleased to announce that its Formulation Manufacturing…
“Automation is critical to improve operational efficiency and accelerate innovation” – Subodh Deshmukh and Ramesh Subramanian
What were the main highlights from Aragen in 2023? RS: 2023 was challenging from a macro perspective, as biotech funding was low. Despite this, our…
Home and US CAPEX places India on brink of bioCDMO breakthrough
Indian CDMOs are becoming a major force in the biologics space. Ahead of BIO, we spoke with Aragen, Syngene, and Enzene to discuss responding industry’s…
Three Indian CDMOs ready to seize the BIOSECURE Act opportunity
In the wake of escalating tensions between the United States and China, the Biden Administration is intensifying its strategic focus on biosecurity. “The BIOSECURE Act…
Biosecurity threats and business as usual
A new version of a United States congressional bill (the Biosecure Act) that restricts US companies from doing business with certain Chinese biotechnology organisations, including…
CDMO trends post-Wuxi’s exit from the US: who will take its place?
A few months ago, we discussed the WuXi Apptec controversy and the consequences of the BIOSECURE Act on the global biotech industry. For context, the Chinese company…
